INCYTE CORPORATION Decrease in Unrecognized Tax Benefits is Reasonably Possible
INCYTE CORPORATION (INCY) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $22.00 million as of 2023-12-31, per its 10-K filed 2024-02-13.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2024-02-13
- 2023-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $22.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible |
|---|---|
| 2023-12-31 | $22.00M 10-K · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |